StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)

Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –

Niagen Bioscience price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Niagen Bioscience's price to sales ratio was 1.3× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 1.2× to 10.5×, with a median of 2.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.3×−2.8
2025Dec 31, 20254.1×−0.3
2024Dec 31, 20244.4×+3.1
2023Dec 29, 20231.3×−0.4
2022Dec 30, 20221.7×−2.2
2021Dec 31, 20213.9×+3.9
2020Dec 31, 20200.0×−0.0
2019Dec 31, 20190.0×−0.0
2018Dec 31, 20180.0×−12.9
2017Dec 29, 201712.9×+6.0
2016Dec 30, 20166.9×−1.5
2015Dec 31, 20158.5×−0.6
2014Dec 31, 20149.1×−3.0
2013Dec 31, 201312.1×+7.2
2012Dec 31, 20124.9×+0.1
2011Dec 30, 20114.8×–

More Niagen Bioscience figures

See a number that looks wrong?